Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.

@article{Andes2005TreatmentOI,
  title={Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.},
  author={David R Andes and William A P Craig},
  journal={Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases},
  year={2005},
  volume={11 Suppl 6},
  pages={10-7}
}
Susceptibility surveillance investigations have demonstrated an increased incidence of ESBL-producing Gram-negative bacilli. Case cohort studies have suggested clinical relevance associated with ESBL-producing Enterobacteriaciae infection. Yet, current laboratory reporting guidelines classify a large percentage of these organisms in the susceptible category. The regulatory agencies Clinical Laboratory Standards Institute (formly NCCLS) and EUCAST, which oversee these guidelines are in the… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

Similar Papers

Loading similar papers…